SHL Medical

SHL Medical designs, develops, and manufactures advanced drug delivery devices such as autoinjectors, pen injectors, inhalers and wearable drug delivery systems, and provides final assembly, labelling, and packaging services for leading pharmaceutical and biotech companies across the globe.

Associated Companies

Weibel CDS

Switzerland
SHL Medical AG
Gubelstrasse 22
6300 Zug
Switzerland

Phone / Contact

T: +41 41 368 00 00
E: [email protected]

Connect

SHL Medical is a solutions provider in the design, development and manufacturing of advanced drug delivery systems such as autoinjectors, pen injectors, inhalers and wearable drug delivery systems. SHL offers final assembly, labelling, and packaging solutions for drug delivery devices, and provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

SHL has locations in Switzerland, Taiwan, Sweden, and the US. Significant investments in R&D have enhanced its broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high-volume and high-viscosity formulations and can be enhanced through digital implementations.

SHL is best known for its portfolio of autoinjectors and technologies for self-injection, including the Molly® family of autoinjectors, the Rotaject® technology for high-volume and high-viscosity formulations, and the Needle Isolation Technology (NIT®), a unique safety solution for cartridge-based autoinjectors.

In March 2020, SHL acquired Swiss patch injector and parenteral injection medical technology company Weibel CDS.

SHL Medical is privately owned. It was founded in 1989 and now employs more than 5,000 people globally. SHL works with the majority of the world’s top 25 largest pharma companies.

Articles by SHL Medical

Dr Veluska Bruce

MAKING LOW-CARBON-EMISSION SINGLE-USE MEDICAL DEVICES A REALITY

Veluska Bruce discusses the design and development of single-use autoinjectors in the context of sustainable development.

INDUSTRIALISATION

Edwin Hendrawan

AN AUTOINJECTOR REVOLUTION: ADVANCED SIMULATION TECHNOLOGIES ENHANCING GLOBAL MANUFACTURING NETWORKS

Edwin Hendrawan, Yi-Chi Lu and Christian Walter set out how SHL is building simulation capabilities, and describe how simulation will propel the business forward on every level, from individual shop floors to overall global expansion planning, in order to be able to meet the growing and increasingly complex demands from both pharma customers and patients.

Chelsea Williams

COLLABORATIVE INNOVATION IN CONNECTED AUTOINJECTORS: HIGH-IMPACT ADHERENCE SOLUTIONS

Chelsea Williams, Nils Weber and Gene Rhode Fuensalida Pantig discuss the potential of collaborative innovation in connected drug delivery when it comes to creating high-impact, low-touch adherence solutions.

Michael McGowan

ENABLING LARGE-VOLUME, HIGH-DOSE SUBCUTANEOUS AUTOINJECTIONS WITH CARTRIDGE-BASED TECHNOLOGIES

Michael McGowan, examines the emerging interest in autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space and considers the potential benefits of SHL Medical’s cartridge-based 3 and 5 mL Maggie^® autoinjectors.

Gary Calderwood

ENLARGING THE VOLUME OF AUTOINJECTORS: TRAVERSING INJECTION BOUNDARIES

Gary Calderwood, Raluca Ganea and Gene Rhode Fuensalida Pantig review how the parenteral space has transformed over the past decade and reports how the company’s portfolio of autoinjector technologies has evolved to deliver subcutaneous parenteral drugs of varying formulations, including higher administration volumes.

INDUSTRIALISATION

CONTINUOUS IMPROVEMENT: FROM ABSTRACTION TO REALITY

Tracy Pedreso discusses SHL Medical’s strategy for making continuous improvement a reality.

Chelsea Williams

MEETING AN UNMET PHARMA NEED: PIONEERING THE WAY TO A CONNECTED FUTURE

Chelsea Williams, Nagisa Kobashi and Nils Weber discuss the digital transformation of injectables, where drug formulation and device are enmeshed within a connected ecosystem powered by patient data.

Jonathan Kearns

PUTTING PROCESS ENGINEERING INTO ACTION

Jonathan Kearns and Kevin Huang consider how engineering competencies are being driven to the next level by leveraging process engineering and how this can transform drug-device projects.

Frederick Gertz

DATA-DRIVEN SUSTAINABILITY IN AUTOINJECTOR DEVELOPMENT

Frederick Gertz and Yves Steffen outline the company’s approach to sustainability, involving leveraging the experience of its data science department to enhance the output of its sustainability department.

CREATING TIMELESS DEVICE TECHNOLOGIES

Andrew Moore and Gene Rhode Fuensalida Pantig discuss the importance of a sound strategy for product lifecycle management.

INDUSTRIALISATION

DEVELOPING A FULLY AUTOMATED MODULAR MACHINE PLATFORM FOR AUTOINJECTOR TESTING

Lucy Chung and Gilbert Fluetsch discuss the benefits of a modular automated test platform.

Markus Goldinger

FROM PROCESS TO PRODUCT: OPTIMISING PROCESS DEVELOPMENT STRATEGIES FOR VARIABLE DRUG-DEVICE REQUIREMENTS

Markus Goldinger and Erik Alexandersson discuss the benefits to process development provided by SHL’s fully in-house, vertically integrated model, and how those benefits are applied throughout the process from initial design work to final assembly of the drug delivery device and primary container.

INDUSTRIALISATION

THE “CUSTOMISABLE PLATFORM” PARADOX

Lyndon Wild and Gene Rhode Fuensalida Pantig present a systematic analysis of the customisable platform architecture found in the Molly^® autoinjector technology.

INDUSTRIALISATION

Frederick Gertz

APPLICATIONS OF DEEP LEARNING IN MEDICAL DEVICE MANUFACTURING

Frederick Gertz and Gilbert Fluetsch look at how deep learning can be leveraged in a medical device manufacturing environment.

Chelsea Williams

DIGITAL HEALTH REFORMULATION: FROM HOPE TO HYPE TO HEALTH

Chelsea Williams, Ramin Rafiei and Ralph Howald discuss the accelerating value of digital health to improve the patient experience, achieve improved health outcomes, and increase health system efficiency and value.

Frederick Gertz

ESTABLISHING DATA-DRIVEN DESIGN AND MANUFACTURING FOR MEDICAL DEVICES

Frederick Gertz explores the benefits for medical device design and manufacturing organisations of adapting to the use of big data and analytics.

PREFILLED SYRINGES

Gene Rhode Fuensalida Pantig

ADDRESSING COMPLEX BIOLOGICS WITH RATIONAL DRUG DEVICE DESIGN

Gene Rhode Fuensalida Pantig reviews drug development over the years, the discovery of biologics as therapeutic agents and the emergence of autoinjectors, in correspondence with Hans Lin, PhD, a Research Fellow from Academia Sinica, Taiwan.

Michael McGowan

30 YEARS IN THE MAKING – AN INSIDE PERSPECTIVE ON THE EMERGENCE OF AUTOINJECTORS

Michael McGowan, Director of Market Intelligence at SHL Group, gives a perspective on the emergence of the autoinjector as a key component of the drug delivery industry, in the context of SHL celebrating its 30th anniversary this year – a journey of rapid development that reflects the growing demand for advanced drug delivery systems in the healthcare market.

INDUSTRIALISATION

Gilbert Fluetsch

EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES

Gilbert Fluetsch and Lucy Chung look at how automation and assembly services can best evolve and adapt to industry standards and market demands, whilst delivering consistently at high quality and in a timely manner.

Dr Ramin Rafiei

MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY

Ramin Rafiei argues that connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.

PREFILLED SYRINGES

SOLUTIONS FOR HIGH-VOLUME DRUG DELIVERY

SHL Group introduces the high-volume variation of its Molly^® family of products, the Molly^® 2.25, and discusses more broadly the advantages that the Molly^® business model offers to pharmaceutical and biotech clients.

PREFILLED SYRINGES

Michael McGowan

VOICE OF CUSTOMER RESEARCH – A CUSTOMER-CENTRIC APPROACH TO STRATEGY DEVELOPMENT

Michael McGowan discusses SHL’s view on adapting to the shifts in market needs and stakeholder priorities in the pharma and biotech sectors, and details how SHL has implemented a “voice of customer” market research programme to ensure it provides the best possible service for its customers.

PREFILLED SYRINGES

FINAL ASSEMBLY, LABELLING & PACKAGING

For the development of combination products, pharma and biotech companies have the option to establish an assembly and packaging infrastructure internally or to outsource to a contract manufacturing organisation. One such organisation, SHL, explains what the benefits are of using a manufacturing partner and outlines what it can offer in terms of an integrated process.

PREFILLED SYRINGES

INJECTING HIGH VOLUME, HIGH VISCOSITY DRUGS

SHL details its latest offerings in the world of biologics, as well as its partnership with QuiO, a speciality digital healthcare start-up, to develop injectables in the connected healthcare space.

Top